Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
piflufolastat F 18 + gadolinium
- Development stage
- Unknown
- Lead developer
- Lantheus
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
piflufolastat F 18 + gadolinium is a diagnostic drug combination used in positron emission tomography (PET) and magnetic resonance imaging (MRI) for the evaluation of prostate cancer. Piflufolastat F 18 (also known as 18F-DCFPyL or Pylarify) is a second-generation, small-molecule radiopharmaceutical that targets the prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells. Gadolinium is a paramagnetic contrast agent used to enhance the structural detail of MRI scans. In clinical research conducted at Stanford University, this combination is utilized in PET/MRI protocols to improve the detection and localization of regional nodal and distant metastases in patients with intermediate to high-risk prostate cancer, offering integrated functional and anatomical imaging that may surpass the sensitivity of standard-of-care CT or MRI alone.
- Brand names
- Pylarify
- Other names
- fluorine-18-labeled DCFPyLfluorine18-labeled DCFPyLfluorine 18-labeled DCFPyLgadolinium-based contrast agent18F-DCFPyL PET/MRI
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on piflufolastat F 18 + gadolinium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on piflufolastat F 18 + gadolinium.